Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04167670
Recruitment Status : Recruiting
First Posted : November 19, 2019
Last Update Posted : December 16, 2020
Sponsor:
Information provided by (Responsible Party):
Phathom Pharmaceuticals, Inc.

Brief Summary:
To compare the efficacy of Helicobacter pylori (HP) eradication with vonoprazan dual and triple therapy regimens versus lansoprazole triple therapy regimen in participants with HP infection, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline.

Condition or disease Intervention/treatment Phase
Helicobacter Pylori Infection Drug: Vonoprazan Drug: Amoxicillin Drug: Clarithromycin Drug: Lansoprazole Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 975 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The triple therapy arms will be blinded to participants, care providers, investigators and outcome assessors. The dual therapy arm will only blinded to the outcomes assessor.
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg Daily in Patients With Helicobacter Pylori Infection
Actual Study Start Date : December 10, 2019
Estimated Primary Completion Date : March 15, 2021
Estimated Study Completion Date : March 15, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vonoprazan dual therapy
Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g, three times daily, for 14 days.
Drug: Vonoprazan
Over-encapsulated tablets administered orally.

Drug: Amoxicillin
Capsules administered orally.

Experimental: Vonoprazan triple therapy
Participants will receive vonoprazan 20 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg, BID, for 14 days.
Drug: Vonoprazan
Over-encapsulated tablets administered orally.

Drug: Amoxicillin
Capsules administered orally.

Drug: Clarithromycin
Tablets administered orally.

Active Comparator: Lansoprazole triple therapy
Participants will receive lansoprazole 30 mg twice daily (BID) in conjunction with amoxicillin 1 g BID and clarithromycin 500 mg BID, for 14 days.
Drug: Amoxicillin
Capsules administered orally.

Drug: Clarithromycin
Tablets administered orally.

Drug: Lansoprazole
Over-encapsulated capsules administered orally.




Primary Outcome Measures :
  1. Number of participants with successful Helicobacter pylori (HP) eradication after the treatment period, excluding participants who had a clarithromycin or amoxicillin resistant strain of HP at baseline [ Time Frame: Week 6 ]
    HP eradication will be determined by carbon-Urea Breath Test (13C-UBT) 4 weeks after the 14 days of treatment.


Secondary Outcome Measures :
  1. Number of participants with successful Helicobacter pylori (HP) eradication after the treatment period, among participants who had a clarithromycin resistant strain of HP at baseline [ Time Frame: Week 6 ]
    HP eradication will be determined by carbon-Urea Breath Test (13C-UBT) 4 weeks after the 14 days of treatment.

  2. Number of participants with successful Helicobacter pylori (HP) eradication after the treatment period, among all participants [ Time Frame: Week 6 ]
    HP eradication will be determined by carbon-Urea Breath Test (13C-UBT) 4 weeks after the 14 days of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The participant is ≥ 18 years of age at the time of informed consent signing.
  2. In the opinion of the investigator or sub-investigators, the participant is capable of understanding and complying with protocol requirements.
  3. The participant signs and dates a written, informed consent form (ICF) and any required privacy authorization prior to the initiation of any study procedures. The participant is informed of the full nature and purpose of the study, including possible risks and side-effects. The participant has the ability to cooperate with the investigator. Ample time and opportunity should be given to read and understand verbal and/or written instructions.
  4. The participant has at least one of the following clinical conditions with confirmed HP+ infection demonstrated by a positive 13C-UBT during the Screening Period.

    • Dyspepsia (i.e. pain or discomfort centered in the upper abdomen) lasting at least 2 weeks
    • A confirmed diagnosis of functional dyspepsia
    • A recent / new diagnosis of (non-bleeding) peptic ulcer
    • A history of peptic ulcer not previously treated for HP infection
    • A requirement for long-term non-steroidal anti-inflammatory drug (NSAID) treatment at a stable dose of the NSAID
  5. A female participant of childbearing potential who is or may be routinely sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from the signing of informed consent until Day -2 and two forms of adequate contraception from Day -1 until 4 weeks after the last dose of study drug.

Exclusion Criteria:

  1. The participant has previously been treated with any regimen to attempt to eradicate HP.
  2. The participant has gastric or duodenal ulcer with endoscopic evidence of current or recent bleeding.
  3. The participant has confirmed diagnosis of gastric cancer by biopsy.
  4. The participant is receiving colchicine.
  5. The participant has received any investigational compound (including those in post marketing studies) within 30 days prior to the start of the Screening Period. A participant who has screen failed from another clinical study and who has not been dosed may be considered for enrollment in this study.
  6. The participant is a study site employee, an immediate family member, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or who may have consented under duress.
  7. The participant has cutaneous lupus erythematosus or systemic lupus erythematosus.
  8. The participant has had clinically significant upper or lower gastrointestinal bleeding within 4 weeks prior to randomization.
  9. The participant has Zollinger-Ellison syndrome or other gastric acid hypersecretory conditions.
  10. The participant has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, titanium oxide, red or yellow ferric oxide), PPIs, amoxicillin and/or clarithromycin, or any excipients used in the 13C-UBT: mannitol, citric acid or aspartame. Skin testing may be performed according to local standard practice to confirm hypersensitivity.
  11. The participant has a history of alcohol abuse, illegal drug use, or drug addiction within the 12 months prior to screening, or who regularly consume >21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week based on self-report. Participants must have a negative urine drug screen for cannabinoids/ tetrahydrocannabinol and non-prescribed medications at screening.
  12. The participant is taking any excluded medications or treatments listed in the protocol.
  13. If female, the participant is pregnant, lactating, or intending to become pregnant before, during, or within 4 weeks after participating in this study; or intending to donate ova during such time period.
  14. The participant has a history or clinical manifestations of significant central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, other gastrointestinal, urological, endocrine or hematological disease that, in the opinion of the investigator, would confound the study results or compromise participants safety.
  15. The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Visit.
  16. The participant has a history of malignancy (including MALToma) or has been treated for malignancy within 5 years prior to the start of the Screening Period (Visit 1) (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).
  17. The participant has acquired immunodeficiency syndrome or human immunodeficiency virus infection, or tests positive for the hepatitis B surface antigen, hepatitis C virus (HCV) antibody or HCV RNA. However, participants who test positive for HCV antibody, but negative for HCV RNA are permitted to participate.
  18. The participant has any of the following abnormal laboratory test values at the start of the Screening Period:

    1. Creatinine levels: >2 mg/dL (>177 μmol/L).
    2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 × the upper limit of normal (ULN) or total bilirubin >2 × ULN.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04167670


Contacts
Layout table for location contacts
Contact: Phathom Medical Information Phathom Pharmaceuticals, Inc. medicalinformation@phathompharma.com

Locations
Show Show 124 study locations
Sponsors and Collaborators
Phathom Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Director Phathom Pharmaceuticals
Layout table for additonal information
Responsible Party: Phathom Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04167670    
Other Study ID Numbers: HP-301
2019-002668-28 ( EudraCT Number )
First Posted: November 19, 2019    Key Record Dates
Last Update Posted: December 16, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Data from this study will be published; however, it is undecided if patient level data will be made available at this time.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Phathom Pharmaceuticals, Inc.:
Vonoprazan
Lansoprazole
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Amoxicillin
Clarithromycin
Lansoprazole
Dexlansoprazole
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors